Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CKDB-314 is a probiotic-based live biotherapeutic product (LBP) being developed by CKDBiO, a subsidiary of Chong Kun Dang. The candidate is specifically designed for the treatment of diabetes, with a primary focus on achieving glycemic improvement. As a microbial therapy, it likely functions by modulating the gut microbiome to influence metabolic pathways, improve insulin sensitivity, and regulate glucose homeostasis. CKDB-314 is currently in the preclinical stage of development within CKDBiO's probiotics pipeline.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CKDB-314.